PROGNOSTIC FACTORS IN THE SURVIVAL OF PATIENTS DIAGNOSED WITH PRIMARY NON-METASTATIC OSTEOSARCOMA WITH A POOR RESPONSE TO NEOADJUVANT CHEMOTHERAPY

被引:36
作者
Bispo Junior, Rosalvo Zosimo [1 ]
de Camargo, Olavo Pires [2 ]
机构
[1] Univ Campina Grande, Fac Med, Campina Grande, PB, Brazil
[2] Univ Sao Paulo, Fac Med, Dept Orthoped & Traumatol, Sao Paulo, Brazil
关键词
Bone neoplasms; Pathology; Epidemiology; Surgery; Drug therapy; HIGH-GRADE OSTEOSARCOMA; PRIMARY OSTEOGENIC-SARCOMA; PREOPERATIVE CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; OPERABLE OSTEOSARCOMA; DELAYED SURGERY; EXTREMITY; INTERGROUP; EXPERIENCE; TUMOR;
D O I
10.1590/S1807-59322009001200007
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
INTRODUCTION: Identification of variables that determine the prognosis for osteosarcoma may enable stratification of patients into subgroups with better or worse risk of local recurrence, metastases and death due to the disease. Discovery of such prognostic factors would permit selection of a subgroup of at-risk patients, with the aim of improving the therapeutic effectiveness. OBJECTIVE: To identify prognostic factors related to local recurrence-free survival, metastasis-free survival and overall survival among patients with highly malignant primary osteosarcoma that was non-metastatic on diagnosis and had poor response to neoadjuvant chemotherapy. SAMPLE AND METHODS: Out of 45 patients admitted to a referral center in Brazil between 2000 and 2004. 24 were selected for this study. RESULTS: The adverse factors that influenced the risk of local recurrence and the overall survival in univariate analysis were histological subtype other than osteoblastic (p = 0.017) and tumor size greater than 15 cm (p = 0.048). In relation to metastasis-free survival, the non-osteoblastic subtype had a worse prognosis (p = 0.007). The association of histological subtype maintained its significance in multivariate analysis for all Studied survival categories. CONCLUSIONS: Tumor size greater than 15 cm is an adverse factor for local recurrence-free survival and overall Survival but did not influence metastasis-free Survival. The osteosarcoma histological type is a significant independent predictor for local recurrence-free survival, metastasis-free survival and overall survival.
引用
收藏
页码:1177 / 1186
页数:10
相关论文
共 51 条
[1]
Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy [J].
Bacci, G ;
Ferrari, S ;
Longhi, A ;
Perin, S ;
Forni, C ;
Fabbri, N ;
Salduca, N ;
Versari, M ;
Smith, KVJ .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (01) :32-38
[2]
Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity - Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor [J].
Bacci, G ;
Bertoni, F ;
Longhi, A ;
Ferrari, S ;
Forni, C ;
Biagini, R ;
Bacchini, P ;
Donati, D ;
Manfrini, M ;
Bernini, G ;
Lari, S .
CANCER, 2003, 97 (12) :3068-3075
[3]
High-grade osteosarcoma of the extremity: Differences between localized and metastatic tumors at presentation [J].
Bacci, G ;
Ferrari, S ;
Longhi, A ;
Forni, C ;
Zavatta, M ;
Versari, M ;
Smith, K .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2002, 24 (01) :27-30
[4]
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli Osteosarcoma-2 protocol: An updated report [J].
Bacci, G ;
Ferrari, S ;
Bertoni, F ;
Ruggieri, P ;
Picci, P ;
Longhi, A ;
Casadei, R ;
Fabbri, N ;
Forni, C ;
Versari, M ;
Campanacci, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) :4016-4027
[5]
BACCI G, 1993, CANCER, V72, P3227, DOI 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO
[6]
2-C
[7]
Baptista André Mathias, 2006, Clinics, V61, P381, DOI 10.1590/S1807-59322006000500003
[8]
Prognostic factors in high-grade osteosarcoma of the extremities or trunk:: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols [J].
Bielack, SS ;
Kempf-Bielack, B ;
Delling, G ;
Exner, GU ;
Flege, S ;
Helmke, K ;
Kotz, R ;
Salzer-Kuntschik, M ;
Werner, M ;
Winkelmann, W ;
Zoubek, A ;
Jürgens, H ;
Winkler, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :776-790
[9]
Tumor size and prognosis in aggressively treated osteosarcoma [J].
Bieling, P ;
Rehan, N ;
Winkler, P ;
Helmke, K ;
Maas, R ;
Fuchs, N ;
Bielack, S ;
Heise, U ;
Jurgens, H ;
Treuner, J ;
Romanowski, R ;
Exner, U ;
Kotz, R ;
Winkler, K .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :848-858
[10]
Prognostic factors and expression of MDM2 in patients with primary extremity liposarcoma [J].
Bispo, Rosalvo Zosimo, Jr. ;
de Camargo, Olavo Pires ;
de Oliveira, Claudia Regina G. C. M. ;
Filippi, Renee Zon ;
Baptista, Andre Mathias ;
Caiero, Marcelo Tadeu .
CLINICS, 2008, 63 (02) :157-164